Efficacy, safety of biosimilar filgrastim similar to that of filgrastim in daily practice
the ONA take:
The clinical effectiveness and safety of biosimilar filgrastim (Zarxio) in daily clinical practice are similar to that of the originator filgrastim for the prevention of chemotherapy-induced (febrile) neutropenia, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the international, prospective, observational, open-label MONITOR-GCSF study, researchers enrolled 1,447 patients with cancer treated with myelosuppressive chemotherapy and receiving prophylaxis with biosimilar filgrastim. Of those, 72.3% received primary prophylaxis and 53.2% initiated prophylaxis between 24 and 72 hours after chemotherapy.
Results showed that 13.2% and 5.9% of patients experienced grade 4 chemotherapy-induced neutropenia and febrile neutropenia, respectively.
Researchers found that 6.1% of patients were hospitalized for (febrile) neutropenia. In regard to safety, 24.7% of patients reported any grade bone pain and 76 patients experienced a total of 148 adverse drug events, of which 4 were serious.
Effectiveness and safety of biosimilar filgrastim (Zarxio) in daily clinical practice are similar to that of the originator filgrastim.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|